SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences (SLS) is highly trending amidst intense community discussion, largely driven by its ability to hold above the critical $5 mark, seen as a gateway for broader institutional interest. Investors are focused on the promising potential of its GPS immunotherapy to transform AML treatment, sparking widespread speculation about a significant revaluation or a potential buyout. This fervor is further amplified by exceptionally high borrow fees and persistent short squeeze narratives among traders.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is experiencing significant community interest, largely driven by its availability on Robinhood and increasing anticipation for the Goliath Mainnet. Investors are actively discussing its potential for institutional adoption and enhanced real-world utility, with many viewing the Binance Futures delisting as a positive catalyst for organic price discovery. The broader crypto market's altcoin season narrative also contributes to bullish sentiment around XCN.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing heightened scrutiny as NVIDIA significantly expands into autonomous driving and humanoid robotics, directly challenging the core growth narratives underpinning TSLA's valuation. Community discussion is sharply divided, with bulls emphasizing Tesla's long-term AI and energy potential, while bears highlight intensified competition, concerns over EV sales, unfulfilled FSD promises, and a recent reiteration of a "Sell" rating by UBS.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is highly discussed amid recent analyst downgrades and an expanded FTC lawsuit concerning its subscription program, sparking debate over its near-term outlook. While some express caution about increasing autonomous vehicle competition, many investors emphasize Uber's robust financials, vast global network, and strategic AV partnerships, believing it is well-positioned to integrate robotaxis and lead the evolving mobility landscape.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF Trust (SPY) is trending as market participants react to recent geopolitical developments surrounding Venezuela, with many attributing recent market rallies to the situation. While some in the community cheer the market's "ATH incoming" momentum and anticipate further gains from upcoming earnings and AI sector strength, others express skepticism, warning of a "bull trap" amidst concerns over dollar stability and underlying economic fragilities. The ongoing conversation highlights a stark divide between those expecting new all-time highs and those bracing for a potential correction.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is prominently trending after announcing a partnership with NVIDIA to integrate its 4D LiDAR as a reference sensor within the NVIDIA DRIVE Hyperion platform ecosystem. This collaboration is widely regarded by the community as a significant validation, fueling discussions about strong market momentum and Aeva's strengthening position in the autonomous vehicle and broader LiDAR sectors.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is actively discussed following recent U.S. action in Venezuela, which included the capture of Nicolas Maduro. The community is polarized, with supporters hailing it as a bold geopolitical move by Donald Trump with potential benefits related to oil and American influence, while critics view it as an illegal intervention and a distraction from other issues. This event is driving significant market sentiment for DJT, given its direct ties to Trump.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a strong market rally, fueled by positive reactions to US geopolitical action in Venezuela impacting oil markets and continued optimism surrounding advancements from major AI chipmakers. While many investors see this as a sustainable climb, others express concern about market fragility and institutional selling masking underlying risks.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus Inc. is experiencing a surge in activity following news of its additive manufactured fuel tank, signaling innovation in spacecraft design and production. This immediate catalyst is fueling intense community discussion around potential short squeeze dynamics, given reported high short interest and a recent private placement. Broader enthusiasm for the space sector is amplifying investor focus on the company's future prospects.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zenas Biopharma Inc.

Zenas BioPharma is trending following its Phase 3 trial results for obexelimab in IgG4-RD. Despite meeting primary endpoints, the community is debating a significant share price drop, attributing it to efficacy comparisons against competitors and a missed milestone payment. Many investors see this as an oversold buying opportunity, while others anticipate continued volatility for this biotech name.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw some unusual options trading on Wednesday. Stock investors bought 3,187 call options on the company. This represents an increase of 407...

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.read more...

<ul class="summary-bullets"><li>The deal includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.</li><li>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta.</li><li>The treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.</li></ul>Repare Therapeutics Inc. (RPTX) shares soared more than 21% in Wednesday’s pre-market trade after the company announced a deal with Gilead Sciences Inc. (GILD) for its investigational cancer treatment.Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million. This includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RPTX">Repare Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing.<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences shares</a> were up around 1% in Wednesday’s pre-market trade. Retail sentiment around the company trended in the ‘neutral’ territory.<h2 class="st-heading-2">More About Repare’s Cancer Treatment</h2>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta. This is associated with BRCA mutations and other genomic alterations.A BRCA mutation is a harmful change in the BRCA1 or the BRCA2 genes that increases the risk for several cancers, including breast, ovarian, prostate, pancreatic, and others. This mutation is inherited and has no symptoms.Repare’s treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.<h2 class="st-heading-2">Boosting Repare’s Cash Balance</h2>Repare stated that the Gilead deal has increased its cash balance, and it is the third portfolio deal entered into by the company this year.Following this deal, Repare estimates that its shareholders will receive $2.2 per share in the pending transaction with XenoTherapeutics Inc. Last month, XenoTherapeutics entered into a definitive agreement to acquire all the issued and outstanding common shares of Repare.Under the deal’s terms, Repare’s shareholders were expected to receive approximately $1.82 in cash per share, along with one non-transferable contingent value right (CVR) per common share. This CVR entitles holders to receive certain future cash payments over 10 years.<a href="https://stocktwits.com/symbol/RPTX">RPTX stock</a> is up 61% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> is up 34%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-stock-market-open-on-christmas-eve/cLesMeFREv2">Is The Stock Market Open Today? Here Are NYSE, Nasdaq Trading Hours On Christmas Eve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Equity

Repare Therapeutics Announces Acquisition of Pol ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to...

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE...

Repare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Hold" by Brokerages

Shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) have earned a consensus recommendation of "Hold" from the five ratings firms that are covering the company, MarketBeat reports. One...

Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their...

HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - RPTX, AXTA, WTG and SEMR

HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - RPTX, AXTA, WTG and SEMR HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm...

Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Consensus Recommendation of "Hold" from Analysts

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are covering the company, Marketbeat Ratings reports. One...

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Repare Therapeutics Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.29	--	--	N/A
Q3 '25	-$0.23	$0.08	134.31%	BEAT
Q2 '25	-$0.56	-$0.39	30.28%	BEAT
Q1 '25	-$0.65	-$0.71	-8.40%	MISSED
Q4 '24	-$0.79	-$0.67	15.10%	BEAT

RPTX
Repare Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RPTX News

RPTXRepare Therapeutics Inc